Aug 27, 2012
Cognitive impairment occurs in a subset of breast cancer survivors after chemotherapy but the incidence remains unknown.
Aug 24, 2012
This podcast discusses the manuscript by Tejpar et al in which patients whose colorectal tumors harbor a specific KRAS mutation, G13D, appear to have benefit in two clinical trials with regard to tumor response and progression-free survival with cetuximab treatment.
Aug 10, 2012
Although historically toxicity was often thought to be a biomarker of efficacy, often it appears to be a marker of dose intensity and individual susceptibility as is the case in this retrospective study of taxane induced peripheral neuropathy and breast cancer outcome.